Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EPS (Weighted Average and Diluted) (2023 - 2026)

BioNexus Gene Lab recorded quarterly EPS (Weighted Average and Diluted) of -$0.22 in Q1 2026, up 43.04% quarter-over-quarter from -$0.4 in Q3 2025, and up 35.16% year-over-year from -$0.17 in Q1 2025.

BioNexus Gene Lab's EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at -$0.22 for Q1 2026.

  • In Q1 2026, EPS (Weighted Average and Diluted) rose 35.16% year-over-year to -$0.22; the TTM figure through Mar 2026 stood at -$1.31 (down 255.01% YoY), while the FY2024 annual figure was -$0.09, up 45.78% from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.22 for Q1 2026 at BioNexus Gene Lab, up from -$0.4 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.61 in Q4 2024 to a low of -$0.75 in Q3 2024.
  • A 4-year average of -$0.15 and a median of -$0.22 in 2026 frame the typical range for EPS (Weighted Average and Diluted).
  • Across the five-year window, EPS (Weighted Average and Diluted) surged 2673.01% in 2024 and tumbled 5683.33% in 2025, its largest moves.
  • BioNexus Gene Lab's EPS (Weighted Average and Diluted) stood at $0.02 in 2023, then soared by 2673.01% to $0.61 in 2024, then sank by 164.33% to -$0.4 in 2025, then surged by 43.04% to -$0.22 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.22, -$0.4, and -$0.34 for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Linde 230.79 Bn 226.84 Bn 4.26 Bn 3.98
2 Chemical & Mining Co Of Chile 127.66 Bn 124.93 Bn 778.60 Mn -
3 Sherwin Williams 72.51 Bn 72.30 Bn 2.78 Bn 2.15
4 Ecolab 70.96 Bn 70.34 Bn 1.85 Bn 1.98
5 Air Products & Chemicals 62.15 Bn 63.70 Bn 987.40 Mn 3.19
6 Ppg Industries 25.04 Bn 23.57 Bn 1.66 Bn 1.70
7 LyondellBasell Industries 21.62 Bn 21.73 Bn 701.00 Mn 0.38
8 Albemarle 20.26 Bn 19.42 Bn 500.97 Mn -
9 DuPont de Nemours 19.45 Bn 19.56 Bn 602.00 Mn 0.36
10 BioNexus Gene Lab 5.34 Mn 1.38 Mn -790.00 -0.23

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.23
Sep 30, 2025 -0.40
Jun 30, 2025 -0.34
Mar 31, 2025 -0.04
Dec 31, 2024 0.61
Sep 30, 2024 -0.75
Jun 30, 2024 0.11
Mar 31, 2024 -0.01
Dec 31, 2023 0.02